ClinicalTrials.gov record
Completed Phase 3 Interventional

Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

ClinicalTrials.gov ID: NCT05078827

Public ClinicalTrials.gov record NCT05078827. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 4:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Multi-center, Three-arm, Parallel-group, Multiple-dose, Placebo Controlled Study to Assess the Therapeutic Equivalence of Fluorouracil Cream USP 5% of Encube Ethicals Pvt. Ltd., India Compared With Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A. in the Treatment of Actinic Keratosis

Study identification

NCT ID
NCT05078827
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Encube Ethicals Pvt. Ltd.
Industry
Enrollment
458 participants

Conditions and interventions

Interventions

  • Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India Drug
  • Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A. Drug
  • Test Product (A): Fluorouracil Cream, 5% topical cream Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2022
Primary completion
Oct 31, 2022
Completion
Nov 30, 2022
Last update posted
Mar 13, 2023

2022

United States locations

U.S. sites
7
U.S. states
3
U.S. cities
6
Facility City State ZIP Site status
CBCC Global Research Site 005 Bakersfield California 93309
CBCC Global Research Site 006 Cerritos California 90703
CBCC Global Research Site 004 Lauderdale Lakes Florida 33308
CBCC Global Research Site 001 Miami Florida 33015
CBCC Global Research Site 002 Miami Florida 33175
CBCC Global Research Site 003 Miramar Florida 33027
CBCC Global Research Site 007 Sugarloaf Pennsylvania 18249

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05078827, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 13, 2023 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05078827 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →